Share This Author
How cells respond to interferons.
- G. Stark, I. Kerr, B. Williams, R. Silverman, R. Schreiber
- BiologyAnnual Review of Biochemistry
- 15 September 1998
The Janus kinases and signal transducers and activators of transcription, and many of the interferon-induced proteins, play important alternative roles in cells, raising interesting questions as to how the responses to the interFERons intersect with more general aspects of cellular physiology and how the specificity of cytokine responses is maintained.
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
A unifying conceptual framework called “cancer immunoediting,” which integrates the immune system’s dual host-protective and tumor-promoting roles is discussed.
Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity
An important role is suggested for CD8α+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection in Batf3–/– mice.
Cancer immunoediting: from immunosurveillance to tumor escape
The historical and experimental basis of cancer immunoediting is summarized and its dual roles in promoting host protection against cancer and facilitating tumor escape from immune destruction are discussed.
Neoantigens in cancer immunotherapy
Observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens.
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
The three Es of cancer immunoediting.
The history of the cancer immunosurveillance controversy is summarized and its resolution and evolution into the three Es of cancer immunoediting--elimination, equilibrium, and escape are discussed.
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
It is demonstrated that Bcl-2 is an integral inner mitochondrial membrane protein of relative molecular mass 25,000 (25k) being localized to mitochondria and interfering with programmed cell death independent of promoting cell division.
Natural innate and adaptive immunity to cancer.
Current experimental and human clinical data supporting a cancer immunoediting process that provide the fundamental basis for further study of immunity to cancer and for the rational design of immunotherapies against cancer are discussed.